Mizuho Reaffirms Neutral Rating for Hologic (NASDAQ:HOLX)

Hologic (NASDAQ:HOLX)‘s stock had its “neutral” rating reaffirmed by Mizuho in a research report issued on Thursday,Benzinga reports. They presently have a $78.00 price objective on the medical equipment provider’s stock, up from their prior price objective of $70.00. Mizuho’s price target suggests a potential upside of 5.51% from the company’s current price.

Several other equities analysts have also recently weighed in on HOLX. UBS Group lifted their price objective on shares of Hologic from $65.00 to $70.00 and gave the stock a “neutral” rating in a research report on Thursday, July 31st. Citigroup upgraded shares of Hologic from a “neutral” rating to a “buy” rating and boosted their price target for the company from $60.00 to $80.00 in a report on Wednesday, July 9th. Raymond James Financial cut shares of Hologic from a “moderate buy” rating to a “hold” rating in a report on Wednesday. Stephens lowered shares of Hologic from an “overweight” rating to an “equal weight” rating and reduced their price objective for the company from $78.00 to $76.00 in a research note on Wednesday. Finally, Royal Bank Of Canada raised shares of Hologic from a “sector perform” rating to an “outperform” rating and boosted their target price for the stock from $72.00 to $87.00 in a research report on Wednesday, August 6th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and thirteen have given a Hold rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $79.23.

Hologic Price Performance

Shares of NASDAQ:HOLX opened at $73.93 on Thursday. Hologic has a 12 month low of $51.90 and a 12 month high of $84.39. The stock has a market cap of $16.44 billion, a price-to-earnings ratio of 30.68, a PEG ratio of 2.54 and a beta of 0.63. The stock’s 50 day moving average price is $67.41 and its 200 day moving average price is $63.76. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.55 and a quick ratio of 2.81.

Hologic (NASDAQ:HOLX) last announced its earnings results on Wednesday, July 30th. The medical equipment provider reported $1.08 EPS for the quarter, topping the consensus estimate of $1.05 by $0.03. Hologic had a return on equity of 19.69% and a net margin of 13.79%.The firm had revenue of $1.02 billion for the quarter, compared to analysts’ expectations of $1.01 billion. During the same quarter in the previous year, the company earned $1.06 earnings per share. The firm’s quarterly revenue was up 1.2% compared to the same quarter last year. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. Equities research analysts anticipate that Hologic will post 4.28 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Christiana Stamoulis sold 7,402 shares of the firm’s stock in a transaction on Monday, October 20th. The shares were sold at an average price of $73.07, for a total transaction of $540,864.14. Following the sale, the director directly owned 47,336 shares in the company, valued at $3,458,841.52. This trade represents a 13.52% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Stephen P. Macmillan sold 138,358 shares of the firm’s stock in a transaction on Monday, September 22nd. The stock was sold at an average price of $66.97, for a total transaction of $9,265,835.26. Following the sale, the chief executive officer owned 1,234,624 shares in the company, valued at approximately $82,682,769.28. The trade was a 10.08% decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.88% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of HOLX. United Services Automobile Association bought a new stake in Hologic in the 1st quarter valued at about $347,000. Dynamic Technology Lab Private Ltd bought a new position in shares of Hologic during the 1st quarter worth approximately $641,000. Nordea Investment Management AB boosted its stake in Hologic by 7.2% during the second quarter. Nordea Investment Management AB now owns 2,587,414 shares of the medical equipment provider’s stock worth $168,674,000 after acquiring an additional 174,828 shares in the last quarter. Cambridge Investment Research Advisors Inc. lifted its stake in shares of Hologic by 1.7% in the first quarter. Cambridge Investment Research Advisors Inc. now owns 32,056 shares of the medical equipment provider’s stock valued at $1,980,000 after buying an additional 528 shares in the last quarter. Finally, Strs Ohio bought a new position in shares of Hologic during the first quarter valued at about $12,910,000. Institutional investors own 94.73% of the company’s stock.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.